Primary malignant tumors of the heart: Four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells

Cardiology

Volumn 105, Issue 4, 2006, Pages 226-233

  Vesely, Brian A ^a   Alli, Abdel ^a   Song, Shijie ^a   Sanchez Ramos, Juan ^a   Fitz, Shannon R ^a   Gower Jr , William R ^a   Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Angiosarcomas; Cardiovascular disease; Malignant tumors of the heart; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR; BRAIN NATRIURETIC PEPTIDE; BROXURIDINE; CYCLIC GMP; DNA; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; UNCLASSIFIED DRUG; VESSEL DILATOR;

ANGIOSARCOMA; ARTICLE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; HEART TUMOR; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ATRIAL NATRIURETIC FACTOR; BLOTTING, WESTERN; CELL PROLIFERATION; DNA; HEMANGIOSARCOMA; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NATRIURETIC PEPTIDES; NUCLEIC ACID SYNTHESIS INHIBITORS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; TUMOR CELLS, CULTURED;

EID: 33646543683     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091816     Document Type: Article

References (40)

1. Colucci WS, Schoen FJ: Primary tumors of the heart; in Braunward E, Zipes DP, Libby P (eds): Heart Disease, ed 6. Philadelphia, Saunders, 2001, pp 1807-1822.
2. Chahinian AP, Gutstein DE, Fuster V: Tumors of the heart and great vessels; in Kufe DW, Pollock E, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF, Frei E III (eds): Cancer Medicine, ed 6. Hamilton, BC Decker, 2003, pp 1475-1477.
3. Donsbeck AV, Ranchere D, Coindre JM, Le Gall F, Cordier JF, Loire R: Primary cardiac sarcomas: an immunohistochemical and grading study with long-term follow-up. Histopathology 1999;34:295-304.
4. Vesely BA, McAfee Q, Gower WR Jr, Vesely DL: Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 2003;33:998-1005.
5. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SM, Gower WR Jr, Vesely DL: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 2005;35:60-69.
6. Vesely BA, Fitz SR, Gower WR Jr, Vesely DL: Vessel dilator: most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett 2006;232:226-231.
7. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Alli A, Solivan SM, Gower WR Jr, Vesely DL: Five cardiac hormones decrease the number of human small-cell cancer cells. Eur J Clin Invest 2005;35:388-398.
8. Vesely DL, Clark LC, Garces AH, McAfee QW, Soto J, Gower WR Jr: Novel therapeutic approach for cancer using four cardiovascular hormones. Eur J Clin Invest 2004;34:674-682.
9. Gardner DG, Kovacic-Milivojevic BK, Garmai M: Molecular biology of the natriuretic peptides; in Vesely DL (ed): Atrial Natriuretic Peptides. Trivandrum, Research Signpost, 1997, pp 15-38.
10. Vesely DL: Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 2002;53:153-159.
11. Vesely DL: Natriuretic hormones; in Alpern RJ, Hebert SC (eds): The Kidney: Physiology and Pathophysiology, ed 4. San Diego, Elsevier/Academic Press, in press.
12. Vesely DL, Norris JS, Walters JM, Jespersen RR, Baeyens DA: Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem Biophys Res Commun 1987;148:1540-1548.
13. 2-terminus are natriuretic and/or kaliuretic. Am J Physiol 1990;258:F1401-F1408.
14. 2. J Clin Invest 1992;89:1411-1417.
15. Benjamin BA, Peterson TV: Effects of proANF (31-67) on sodium excretion in conscious monkeys. Am J Physiol 1995;269:R1351-R1355.
16. + reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 1995;22:121-124.
17. Villarreal D, Reams GP, Taraben A, Freeman RH: Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med 1999;221:166-170.
18. Dietz JR, Scott DY, Landon CS, Nazian SJ: Evidence supporting a physiological role for proANP (1-30) in the regulation of renal excretion. Am J Physiol 2001;280:R1510-R1517.
19. Vesely DL, Douglass MA, Dietz JR, Giordano AT, McCormick MT, Rodriguez-Paz G, Schocken DD: Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 1994;78:1128-1134.
20. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G, Schocken DD: Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans. Circulation 1994;90:1129-1140.
21. Vesely DL, Dietz JR, Parks JR, Baig M, McCormick MT, Cintron G, Schocken DD: Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 1998;98:323-329.
22. Vesely DL: Atrial Natriuretic Hormones. Englewood Cliffs, Prentice Hall, 1992, pp 1-256.
23. Barr CS, Rhodes P, Struthers AD: C-type natriuretic peptide. Peptides 1966;17:1243-1251.
24. Lainchbury J, Richards AM, Nicholls MG: Brain natriuretic peptide in heart failure; in Vesely DL (ed): Atrial Natriuretic Peptides. Trivandrum, Research Signpost, 1997, pp 151-158.
25. Vesely DL: Natriuretic peptides and acute renal failure. Am J Physiol 2003;285:F167-F177.
26. Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL: The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989;80:438-449.
27. Vesely DL, Norsk P, Winters CJ, Rico DM, Sallman AL, Epstein M: Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med 1989;192:230-235.
28. Hunter EFM, Kelly PA, Prowse C, Woods FJ, Lowry PJ: Analysis of peptides derived from proatrial natriuretic peptide that circulate in man and increase in heart disease. Scand J Clin Lab Invest 1998;58:205-216.
29. Franz M, Woloszczuk W, Horl WH: N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int 2000;58:374-378.
30. De Palo EF, Woloszczuk W, Meneghetti M, De Palo CB, Nielsen HB, Secher NH: Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin Chem 2000;46:843-847.
31. Franz M, Woloszczuk W, Horl WH: Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int 2001;59:1928-1934.
32. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N: Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997;94:861-866.
33. Gratzner HG: Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982;218:474-475.
34. Qin Y, Williams G: Comparison of the classical autoradiographic and immunohistochemical methods with BrdU for measuring proliferation parameters in colon cancer. Anticancer Res 1993;13:731-736.
35. Waldman SA, Rapoport RM, Murad F: Atrial natriuretic factor selectively activates membranous guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 1984;259:14332-14334.
36. Vesely DL: Signal transduction: activation of the guanylate cyclase-cyclic guanosine-3′5′ monophosphate system by hormones and free radicals. Am J Med Sci 1997;314:311-323.
37. Suga SI, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirmakami G, Arai H, Saito Y, Kambayashi Y, Inoye K, Imura H: Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992;130:229-239.
38. Murthy KS, Teng B, Jin J, Makhlouf GM: G-protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor. Am J Physiol 1998;275:C1409-C1416.
39. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
40. Vaporciyan AA, Kies M, Stevens C, Komaki R, Roth JA: Cancer of the lung; in Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E III (eds): Cancer Medicine, ed 6. Hamilton, BC Decker, 2003, pp 1385-1445.